INTRODUCTION
Von Willebrand factor (VWF) is a multifunctional plasma protein that plays a predominant role in the events that lead to normal arrest of bleeding. VWF is produced by endothelial cells and megakaryocytes and originates from the VWF precursor (pro-VWF), processing of which results in the formation of two large polypeptides, mature VWF and the VWF propeptide (also named VWAgII). Both polypeptides have distinct biological functions. Mature VWF both mediates the adhesion of blood platelets at sites of vascular injury and functions as a stabilizing carrier protein of factor VIII, an essential cofactor of the coagulation system. Its physiological significance is underscored by the well known observations that qualitative or quantitative defects, or von Willebrand's disease, may predispose to a severe bleeding diathesis, both because of defective platelet plug formation and abnormal blood clotting at sites of vascular injury. In addition to its well defined role in platelet adhesion and regulation of the coagulation system, VWF may help to anchor endothelial cells to the extracellular matrix. The propeptide of VWF is required for proper posttranslational multimerisation and subsequent storage of VWF. In the last few years, increasing evidence has been obtained that the VWF propeptide might also be involved in a variety of biological processes after it is secreted. It both may modulate platelet function and may act as an inflammatory mediator.
The biosynthesis and the properties of VWF have been reported in comprehensive reviews [1, 2] . Here we will briefly discuss the major molecular events associated with its biosynthesis, storage and secretion by endothelial cells. Subsequently, we will focus on the function of VWF as a chaperone protein for factor VIII. In addition, we concentrate on the unusual pleiotropic nature of the VWF propeptide.
BIOSYNTHESIS OF VON WILLEBRAND FACTOR
In the early 1970s, immunohistochemical studies revealed that antibodies to the factor VIII-VWF complex recognized immunoreactive material associated with the endothelium of a variety of human tissues [3, 4] . Soon it became clear that endothelial cells from large and smaller veins, capillaries, aorta and arteries indeed synthesize and secrete VWF [5, 6] . More recent studies have demonstrated that the VWF gene is differentially expressed in endothelial cells present in different tissues [7] . Besides endothelial cells, also platelets contain VWF produced by the platelet precursor, the megakaryocyte [8, 9] .
VWF is a typical example of a secretory protein. The molecular events associ-
The molecular events associated with the biosynthesis of VWF occur, in terms of time and space, in highly ordered manner (Fig.1 ). Molecular cloning of the full length human VWF cDNA revealed that the mRNA is translated as a pre-propolypeptide, composed of a signal peptide of 22 amino acids, an unusually large pro-peptide of 741 amino acids, and mature a VWF molecule of 2050 amino acid residues. These features indicate that the pre-pro-protein undergoes two proteolytic processing steps before it enters the circulation: cleavage of the signal peptide by a signal peptidase and subsequent cleavage of the propeptide after the arginine residue at position 763 1 by an endoprotease. A remarkable feature of the VWF precursor protein is its highly repetitive structure. The pro-protein is almost entirely (over 90%) composed of four types of repeated domains (A-D) exhibiting internal ated with the biosynthesis and secretion of VWF are, to a large extent similar to the processing steps and routing of many other proteins destined to be externalized. In one respect the biosynthesis of VWF distinguishes itself from the synthesis of most other proteins produced by endothelial cells, in that, at least part of the newly synthesized protein is stored in characteristic organelles, called Weibel-Palade bodies (see below). homologies, that are each present in two to five copies (Fig.2) . VWF probably has a complex evolutionary history marked by repeated gene segment duplications and exon shuffling. To a certain extent these domains exert autonomous functions. Roughly speaking a number of distinct binding functions of VWF co-localize with a particular domain. Comparison of the protein sequences revealed that these domains share similarity with distinct, apparently unrelated structural motifs in a number of other proteins with binding functions, including integrins, components of the complement system, thrombospondin and collagens (reviewed in [2] ). Also characteristic for the pro-VWF structure is the occurrence of Arg-Gly-Asp (RGD) sequences. One RGD sequence is located near the carboxyterminal region of the propeptide and one is located near the carboxy-terminal end of the C1 domain. There is ample evidence that the latter RGD sequence is essential for the binding of VWF to platelets [10] . Whether the propeptide RGD sequence plays a similar function has not been established. The RGD motif is not present in the bovine propeptide moiety of pro-VWF, suggesting an insignificant role of this sequence in controlling functional modalities of the propeptide [11] .
After cleavage of the signal peptide and translocation in the ER, the primary translation product undergoes N-linked glycosylation and dimerisation ( Fig.1) [1] . Dimerisation occurs through disulfide bonds within the carboxy-terminal amino acids of the pro-VWF subunits [12, 13] . The pro-VWF dimers are then transported to the Golgi apparatus and post-Golgi compartments, where the high mannose oligosaccharides are processed to the complex form and also sulphation and O-linked glycosylation take place [1, 14] . Simultaneously to these post-translational processes, the processed pro-VWF dimers polymerize during the travel through the Golgi compartments. Consecutively, pro-VWF is transported to the trans-Golgi network where further multimerisation and proteolytic cleavage occur, yielding mature VWF multimers and propeptide dimers. After cleavage, VWF and the VWF propeptide remain non-covalently associated, at least within the cell [15] .
Detailed analysis of the secondary structure of VWF revealed that inter-subunit disulfide bonds are localized in an amino-terminal region (residues 1046-1458) and carboxy-terminal region (amino acid residues 2671-2813), beyond the domain C2 [13] . Although polymerisation of VWF dimers by formation of intermolecular disulfide bonds located within the D3 domains is apparently not affected by carboxyterminal disulfide bond formation (and vice versa), polypeptide regions upstream of the domain D3 do control polymerisation. For instance, if the domain D' is deleted or harbors certain point mutations, no multimers are formed [16, 17] Similarly, deletion of the propeptide, or missense mutations within the propeptide region, results in defective polymerisation [18] [19] [20] [21] . These observations can be interpreted in terms of a "zipper model" which proposes that both propeptide and the domain D' serve to properly align the dimers for inter-dimer crosslinking. Pertinent to this point is the ability of the (cleaved) propeptide to form dimers through non-covalent interactions [22, 23] .
Accumulated data suggest that the propeptide not only plays a role in positioning the protomers but may also catalyse crosslinking of the D3 domains. Indeed, when mature VWF, devoid of the propeptide, is co-expressed with the free propeptide, each in a separate vector, polymerisation does occur [19] . Moreover, alteration of the primary structure of those peptide regions within the D domains of the propeptide that are highly homologous to the active site of proteins harboring protein disulfide isomerase (PDI) activity, abolishes polymerisation [23] . PDI is the enzyme that catalyses thiol-disulfide interchange reactions in protein substrates leading to disulfide formation and folding of the protein [24] . These observations suggest that the ability of the propeptide to promote interchain disulfide bonding can be ascribed to intrinsic PDI activity of the propeptide. In this respect, the VWF propeptide acts as a intramolecular chaperone protein [25] .
The polymerisation process is accompanied by cleavage of the dimer form of the precursor into mature VWF and the free propeptide [26] . The propeptide cleavage occurs at a dibasic site, one of the most common processing motifs in mammalian pro-proteins and prohormones [27] . Two members of the eukaryotic subtilisin-like protease family, furin (also called PACE) and PACE4, were shown to process pro-VWF to its mature form [28, 29] . These proteases share the same cleavage site but have different substrate specifcities [30] . Most likely, furin is the enzyme responsible for pro-VWF cleavage within the endothelium [31, 32] .
STORAGE OF VWF BY ENDOTHELIAL CELLS IN WEIBEL-PALADE BODIES
VWF distinguishes itself from many other endothelial proteins in that it can be secreted from the cell by more than one pathway, the constitutive and the regulated pathway (Fig.3) . The constitutive secretory nature of the endothelium is reflected by the observation that soon after synthesis, VWF accumulates extracellularly in the absence of a stimulus [33] . On the other hand, if endothelial cells are exposed to agonists that give rise to an increase of cytosolic free Ca 2+ ([Ca   2+ ] i ), such as thrombin, histamine or the calcium ionophore A23187, or to cAMP-raising agents, such as epinephrine or forskolin, VWF is rapidly secreted by the cell [34] [35] [36] . The rate of The largest proportion of the VWF species, consisting of partially processed and inmature VWF, is secreted through the constitutive pathway. The remainder, the largest, fully processed and functional VWF, is sorted into Weibel-Palade bodies and secreted via the regulated pathway. This model proposes that the majority of VWF is secreted through the constitutive pathway [48] this type of secretion is much higher than the biosynthetic rate of VWF. The stimulus-induced secretion of VWF originates from storage vesicles, previously identified as Weibel-Palade bodies [37] . These vesicles are endothelial cell-specific elongated organelles, enclosed by a limiting membrane, which are about 0.1 µm wide and up to 4 µm long [38] . Besides VWF, Weibel-Palade bodies have been shown to contain a subset of other proteins, including P-selectin and endothelin (Table 1) . Similar to VWF, these proteins can be secreted upon demand by endothelial cells upon stimulation by Ca 2+ -or cAMP agonists. Apparently, Weibel-Palade bodies are not only restricted for VWF storage.
Electron microscopical studies revealed that Weibel-Palade bodies most likely originate from the trans-Golgi network [39] . Immunostaining of ultrathin frozen sections of cultured endothelial cells revealed that, together with apparently mature Weibel-Palade bodies, densely packed VWF, surrounded by a limiting membrane, is occasionally found in close apposition with the trans-Golgi network [40] . This observation supports the view that VWF-containing storage vesicles emerge through budding from the Golgi complex, an event generally associated with the secretion of proteins in eukaryotes [41] . It has been proposed that targeting of VWF to Weibel-Palade bodies occurs as a consequence of selective aggregation, by means of multimerisation of this protein in the trans-Golgi network [40, 42] . However, evidence has been obtained that VWF-multimerisation is not the sole targeting signal. It has been proposed that the propeptide could also play a role in this process [23, 43] . Apparently, the sorting mechanism is more complex than previously understood.
VON WILLEBRAND SECRETION AND CATABOLISM
Regulated secretion of VWF involves the translocation of Weibel-Palade bodies from the cytoplasm towards the plasma membrane and fusion of these vesicles with the plasma membrane. These events are regulated by second messengers in response to [Ca 2+ ] i -or cAMP raising agents. There is ample evidence that G proteins are involved in the [Ca 2+ ] i -mediated VWF secretion by endothelial cells (Fig.4) [ [44] [45] [46] . However their role in cAMP-dependent exocytosis remains to be established. Qualitative differences in Weibel-Palade body secretion are observed in response to [Ca 2+ ] i -and cAMP agonists [46] . [Ca 2+ ] i induces release of both peripheral and central granules, whereas cAMP involves only vesicles located in the periphery of the cell. It is worth noting that the role of 1-deamino-8-D-arginine vasopressin (DDAVP), which is widely used to raise plasma VWF and factor VIII levels in patients with von Willebrand's disease and haemophilia A, has recently been delineated [47] . It has been shown that DDAVP can directly induce VWF secretion from human microvascular endothelial cells by activation of the vasopressin V2 receptor (V2R). This process is mediated by a rise in cAMP.
PHYSIOLOGICAL SIGNIFICANCE OF VWF PROCESSING AND SECRETION.
As outlined above, expression of the VWF gene is associated with a number of post-translational modifications, including a discrete endoproteolytic cleavage step. The latter step results in the generation of mature VWF and the propeptide moiety of pro-VWF. Subsequently these polypeptides are released to the outside of the cell, either directly or after appropriate stimulation of the cell. After release, VWF and its propeptide have divergent fates. VWF serves a role in controlling platelet adhesion and aggregation and acts as a chaperone protein for factor VIII; the propeptide may act as an antagonist of platelet function and may serve a role as an inflammatory mediator. Little is known about the physiological significance of the diversity of processing, secretion and the ability of endothelial cells to store VWF. It seems reasonable to assume that a subset of biologically active VWF polymers become readily available in the vicinity of the injured vessel upon activation of endothelial cells and subsequent exocytosis of Weibel-Palade bodies (for instance induced by thrombin formed locally as a result of vascular damage). In particular these VWF species play a prominent role in controlling platelet adhesion and aggregation (and possibly controlling factor VIII function, see below). Because of its limited degree of polymerisation, VWF released through the constitutive pathway would be less efficient in this respect. In vitro studies have shown that a significant portion of de novo synthesised VWF is secreted through the constitutive pathway as partially processed, incompletely polymerised and functionally incompetent protein [48] . Only fully processed, substantially polymerised and functionally mature VWF is stored in the Weibel-Palade bodies, together with its propeptide (Fig.3) . To what extent the plasma VWF pool stems from the constitutive route in vivo, is unknown. Only trace amounts of pro-VWF are detectable in plasma [49] . This suggests that under normal physiological conditions the constitutive pathway does not substantially contribute to the release of VWF. On the other hand, it is possible that after release pro-VWF is rapidly cleared from the circulation or, alternatively, converted into mature VWF and propeptide outside the cell. Indeed, animal experimental studies have shown that upon infusion of (unprocessed) pro-VWF the VWF propeptide is rapidly cleaved from its precursor [50] . It remains unclear, therefore, to what extent release through the constitutive pathway plays a role in the replenishment of the plasma VWF pool. In any case, only mature VWF and its propeptide are detectable in plasma in significant amounts (50 and 5 nM respectively), not their precursor, pro-VWF [49] .
FUNCTIONS OF VWF
After its release from the endothelium (and platelets) VWF serves two essential biological functions: it mediates the adhesion and aggregation of platelets at sites of vascular injury and modulates the survival and function of factor VIII. In addition, proper haemodynamic conditions (high shear rate) and highly polymerised VWF molecules are required to ascertain efficient platelet adhesion and aggregation. The molecular basis and physical chemical backgrounds of events associated with VWF-mediated platelet functions are well documented (reviewed in [2] and [10] ). The factor VIII chaperone function of VWF is less well understood and this unique property will be discussed here.
Factor VIII binding VWF circulates in plasma with factor VIII as a non-covalent complex. This interaction extends the survival of factor VIII in the circulation. Any change in plasma VWF level is coupled with a concordant change in the plasma concentration of factor VIII. For instance, low VWF levels, as in von Willebrand's disease, are associated with low plasma factor VIII levels as well. Similarly, qualitative VWF defects, as in von Willebrand's disease type 2N (see below), may abolish proper factor VIII-VWF interactions and, as a consequence, plasma factor VIII levels are decreased. In clinical conditions associated with elevated VWF levels, such as malignancies, sepsis or liver disease, factor VIII levels seem to increase in a coordinate fashion [51, 52] . Similarly, also physiological stimuli such as exercise or pregnancy enhance VWF levels with a concomitant rise in factor VIII levels. These examples clearly illustrate that VWF is essential for the stabilisation of factor VIII in the circulation. The opposite is not the case; plasma VWF levels are not influenced by factor VIII levels.
The molecular basis of the factor VIII-VWF complex formation is fairly well understood, at least the polypeptide domains and interactive sites of the VWF and factor VIII molecule that mutually interact have been identified (reviewed in [53] ). The amino-terminal D' domain of VWF comprises the primary factor VIII binding site [54] . Only in its dimeric form this Cys-rich domain is able to bind factor VIII, indicating a complex mode of protein-protein interaction. In patients with a markedly decreased affinity of their VWF with (otherwise normal) factor VIII, (socalled von Willebrand's disease type 2N) several missense mutations in VWF have been identified that selectively abolish factor VIII binding [55, 56] . The majority of mutations were localized to the D' domain. In most (though not all) cases reported these mutations do not affect the plasma VWF levels or the reactivity of VWF with platelets or the subendothelial connective tissue. Only the affinity for factor VIII is decreased. Recent studies indicate that multiple amino acid residues within the D' domain are critical in stabilising the conformational structure of this domain and, as a consequence, factor VIII binding [17, 57] . The complementary interactive sites for VWF on the factor VIII molecule have also been identified (reviewed in [53] ). VWF not only binds to factor VIII and thereby controls its biological survival, it also protects factor VIII from premature proteolytic cleavages and inactivation. Possibly biological survival and proteolytic degradation are interconnected, though a causal relationship has not been identified. VWF and factor VIII are probably synthesized by different cell types [53] and during or after release into the circulation these proteins form a tight, non-covalent complex. Each VWF monomer is able to bind one factor VIII molecule. However, in vivo not all VWF monomers are bound to factor VIII. Rather a relatively small portion (1-2%) of the available VWF monomers is occupied by factor VIII [58] . These complexes are relatively stable. Only upon triggering of the coagulation system one of the VWF-binding sites on the factor VIII molecule is cleaved off, notably by thrombin, resulting in dissociation of the complex and subsequent conversion of factor VIII into its active configuration (factor VIIIa) [59] .
VWF modulates the function of factor VIII at various levels. It inhibits the interaction of factor VIII to different proteases of the coagulation system, including factor IX, factor X, protein C as well as negatively charged phospholipid membranes, thereby preventing premature activation of the coagulation system. These interactions most likely play a significant role in controlling haemostatic responses to vascular injury. There is indeed ample evidence that VWF can protect factor VIII against proteolytic degradation, at least in vitro (reviewed in [53] ). It seems reasonable to assume, therefore, that the decreased half-life of factor VIII in the absence of VWF is due to premature cleavages of factor VIII and subsequent enhanced clearance of the proteolytically modified factor VIII molecule. However, experimental data in support of this view is lacking so far.
Recent reports have shown that VWF could also control the biological half-life of factor VIII by controlling its interaction with LRP (low density lipoprotein receptor-related protein) [60] . LRP is a multifunctional scavenger receptor involved in the clearance of a spectrum of ligands, including proteases, protease-inhibitor complexes, lipases and apolipoproteins from the circulation (reviewed in [61, 62] ). LRP also binds factor VIII and thereby mediates its cellular internalisation and degradation [63, 64] . These processes are inhibited by VWF. These observations suggest that VWF may also control factor VIII clearance by a mechanism independent of premature proteolytic breakdown of factor VIII. Indeed, in VWF deficient mice the half-life of factor VIII is prolonged by pre-infusion of the animals with RAP, a LRP antagonist [60] . Future studies should reveal the biological significance of the latter clearance mechanism.
Functions of VWF-propeptide
As discussed above, the VWF-propeptide plays an important role in controlling intracellular targeting and polymerisation of VWF. During the maturation of VWF, the propeptide is subsequently cleaved from pro-VWF but is co-stored in the WeibelPalade bodies and co-secreted with mature VWF in response to stimulation of endothelial cells rather than being secreted or degraded as a waste product. Indeed, plasma levels of propeptide (and VWF) are markedly increased under clinical conditions known to be associated with perturbation of the endothelium, such as septicaemia or thrombotic thrombocytopenic purpura (TTP) [65] . It has been thought that, after its release, the propeptide is biologically inert. This is most likely not the case. Accumulating evidence suggests that the propeptide, apart from its presumed PDI activity (see above), possesses a number of functions that could serve a role in controlling inflammatory and cell adhesion processes. Recent studies indicated that the propeptide harbours a number of sites that interact with constituents of the connective tissue of the subendothelium as well as integrins (Table 2) .
Evidence has been obtained that the VWF propeptide specifically binds to collagen type I and is able to inhibit collagen-induced platelet aggregation [66, 67] . The latter effect is probably due to inhibition of the interaction between collagen and the collagen receptor. Detailed analysis of the ability of different monoclonal anti-propeptide antibodies to interfere with the binding of VWF propeptide to collagen revealed that the propeptide contains at least two collagen-binding sites [68] (See Figure 2 above) . One of these peptide domains is located in the first Cys-rich region of the propeptide molecule (Glu ) is involved in collagen binding [69] . Although the VWF propep-tide preferentially binds to native type I collagen fibrils, the Phe 592 -Lys 704 fragment and the decapeptide bind to several other collagens, both in the native as well as in a heat-denatured state. Also mature VWF harbours collagen binding sites (Fig.2) . Peptides regions involved in the latter are structurally distinct from the propeptide binding sites [69, 70] .
The VWF propeptide has also been shown to be present on the surface of platelets [71] . As antibodies to the propeptide may induce platelet activation and aggregation, it has been suggested that membrane-bound propeptide could serve a role in controlling platelet function [72] . The biological significance of the propeptide as a modulator of platelet function remains to be established, however.
A few reports demonstrated that the VWF propeptide is a substrate for coagulation factor XIIIa. This transglutaminase is able to catalyse the cross-linking of the propeptide to laminin, a constituent of the extracellular matrix [73, 74] . The Gln residues in the propeptide specifically reacting with factor XIIIa as amine acceptor have been identified (Fig.2) [74] . Only 4 out of the 40 Gln residues of the propeptide act in this manner, highlighting the specificity of the factor XIIIa-propeptide interaction. As laminin has a variety of cellular functions, including its role as cell attachment or cell migration mediator, it is tempting to speculate that the propeptide could play a role in modulating these processes.
Of particular interest is the observation that the propeptide is able to promote specific adhesion and spreading of certain cell types, in a integrin-dependant manner [75] [76] [77] These processes are mediated by the α4ß1 (VLA4) and the α9ß1 (VLA9) integrins [76, 77] . These integrins bind to the same propeptide site, involving residues 417-432. Interestingly, these integrins also bind factor XIIIa, the enzyme that catalyses the cross-linking of the propeptide to laminin. Both integrins are highly expressed on leukocytes; VLA-4 is primarily expressed by lymphocytes, monocytes and eosinophils, whereas VLA-9 is mostly found on neutrophils [78] . As both integrins play a prominent role in transendothelial migration of these cells, the propeptide could modulate these processes.
Taken together, in addition to its important intracellular function, evidence is accumulating that the propeptide serves a number of extracellular functions, at least in vitro. Future studies should reveal the physiological and pathophysiological significance of these observations.
SCOPE OF THIS THESIS
As outlined above, endothelial cells are able to secrete VWF either constitutively or through the regulated pathway. As illustrated in Figure 5 , storage of VWF in Weibel-Palade bodies is one of the essential steps for its rapid regulated secretion in circulation, and its subsequent function in correct haemostasis. Interestingly, Weibel-Palade bodies are not only restricted to VWF-storage, but are also capable to store and secrete proteins with divergent extracellular functions, among which the VWF-propeptide, P-selectin and IL-8. However, mechanisms such as sorting of proteins to Weibel-Palade bodies, Weibel-Palade body trafficking in the cell and secretion of their content in circulation are far of being understood. Each chapter in this thesis addresses an issue involved in the life cycle of Weibel-Palade bodies or the extracellular function of one of their constituents. Figure 5 illustrates the different steps that were studied in this thesis: The second part of this thesis concentrates on one of the Weibel-Palade body constituent, the VWF-propeptide. In contrast to its well-defined role in controlling intracellular targeting and polymerisation of VWF, less evidence has been provided regarding its biological functions after its release from the cell. Chapter 5, a literature review about the VWF-propeptide, describes in more detail the functions of the propeptide in vascular disorders so far known, including its role as a marker for endothelium perturbation. The latter property of VWF-propeptide served to examine the degree endothelial cell stimulation in patients suffering of thrombotic thrombocytopenic purpura (chapter 6). Chapter 7 focuses on another property of the propeptide, namely its possible role as an inflammatory mediator. The implications of our findings for the unravelling of the life cycle of WeibelPalade bodies are discussed in Chapter 8 and directions for future research are indicated. 
